Source: International Congress 2016 – Pulmonary hypertension: the clinic I
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Mona Lichtblau (Heidelberg, Germany), Mona Lichtblau, Michael Furian, Sayaka Aeschbacher, Maya Bisang, Sara Hartmann, Stefanie Ulrich, Tsogyal Latshang, Almaz Aldashev, Erkin Mirrakhimov, Talant Soronbaev, Konrad E. Bloch, Silvia Ulrich. Dexamethasone reduces pulmonary artery pressure in lowlanders with COPD travelling to 3200m. A randomized, placebo-controlled trial. Eur Respir J 2016; 48: Suppl. 60, 1878

Member's Comments

No comment yet.

Related content which might interest you: Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Exercise training improves peak oxygen consumption and hemodynamics in patients with pulmonary hypertension – A prospective, randomized, controlled trial Source: International Congress 2016 – Best abstracts in pulmonary rehabilitation and chronic care Year: 2016 Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension: A randomised controlled trial (SERAPHIN) Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Effects of Rho-kinase inhibitor fasudil on pulmonary arterial pressure in highlanders with high altitude pulmonary hypertension. (Double-blind placebo-controlled study) Source: Annual Congress 2009 - Pulmonary circulation Year: 2009 Randomized, controlled, prospective multicenter study: Training improves peak oxygen consumption and hemodynamics in patients with chronic severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Effect of nocturnal oxygen and acetazolamide on exercise performance in patients with precapillary pulmonary hypertension and sleep disturbed breathing. Randomized, double-blind, cross-over trial Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Effects of phosphodiesterase type 5 inhibitor on pulmonary hemodynamics in the patients with high altitude pulmonary hypertension (results of 12 week randomized, blind, placebo-controlled study) Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005 An open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Standardised exercise training is feasible, safe and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension - results from a large European multicentre randomised controlled trial Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020 Acute hemodynamic effect of acetazolamide in patients with pulmonary hypertension whilst breathing normoxic and hypoxic air: a randomized cross-over trial Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Effect of acetazolamide on pulmonary hemodynamics in COPD-patients going to altitude: a randomized trial Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension Year: 2019 LATE-BREAKING ABSTRACT: COPD-associated severe pulmonary hypertension (COPDPH): results of a 16-weeks prospective multicenter, double-blind, placebo-controlled randomized clinical trial (RCT) [SPHERIC-1 (http://clinicaltrials.gov/ct2/show/NCT01441934)] investigating the effect of sildenafil citrate (Sld) on pulmonary vascular resistance (PVR) and PaO2. Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 Cicletanine in pulmonary arterial hypertension (PAH): Results from a phase 2 randomized placebo-controlled trial Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012 The effects of beta-blocker therapy on systolic and diastolic function in pulmonary arterial hypertension: A randomized controlled trial Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Pulmonary vasodilator therapy in severe COPD: a double-blind, placebo-controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 525s Year: 2007 Domiciliary high-flow nasal cannula oxygen therapy for stable hypercapnic chronic obstructive pulmonary disease: a prospective, multicentre, randomised crossover trial Source: International Congress 2017 – New insights in chronic respiratory failure Year: 2017 Non-invasive positive pressure ventilation (NIPPV)for acute exacerbations of chronic obstructive pulmonary disease: a multicentre randomized controlled trial Source: Eur Respir J 2003; 22: Suppl. 45, 403s Year: 2003 A randomised, controlled trial of bosentan in severe COPD Source: Eur Respir J 2008; 32: 619-628 Year: 2008 Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES) Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011